Eli Lilly goes on a record $20B shopping spree — ride the momentum as they build beyond weight-loss drugs
Eli Lilly has already spent over $20 billion on acquisitions in 2026, a record pace for the drugmaker. Management is aggressively buying up companies to build new revenue streams beyond its wildly popular weight-loss drugs.
Idea
Lilly's blockbuster obesity drugs have already made it one of the most valuable companies on earth, but management isn't sitting still — they've committed $20 billion to acquisitions in just the first half of 2026 to diversify the business. That kind of aggressive spending signals huge confidence from leadership and gives investors new reasons to buy the stock beyond the obesity narrative. When a company this size goes on a record buying spree, the market tends to re-rate the stock higher as each deal adds growth potential. The key risk is overpaying for deals, but Lilly's track record with the obesity franchise gives them credibility with investors.